Predictors of Mononuclear Cell Yield in Patients Undergoing Autologous Mononuclear Stem Cell Therapy in Non-haemopoietic Degenerative Disorders

Cellular therapy outcomes are influenced by cellular composition of the product. We analyzed the cellular profiles (TNC, MNC and CD34+ cells) of patients receiving mononuclear cell therapy in terms of age, gender, BMI, pre-harvest haematological counts and clinical conditions. Cellular profiles of 262 patients were analyzed in terms of age (age < 40 year, age 41–60 year and age > 60 year), gender, BMI (BMI < 22 kg/m², BMI 22–25 kg/m² and BMI > 25 kg/m²), pre-harvest haematological profile and clinical conditions (chronic disorders, group A, acute vascular group B and traumatic events, group C). A steady decline was observed in TNC and MNC counts with increasing age and BMI. In clinical conditions, group C showed a highest cellular yield followed by group A and group B respectively. Amongst the three age groups, group I (age < 40 year) showed a better cellular profiles than group II (age 41–60 year) and group III (age > 60 year). Patients with Higher TLC (>7000/μl) and platelet count (>200 × 10³/μl) yielded better cellular profile in the harvest. Patient age, BMI, haematological counts and clinical condition significantly affect the bone marrow cellular profile.